BioNTech Updates COVID-19 Vaccine Formulations to Target New SARS-CoV-2 Variants
BioNTech has shifted its strategic focus toward the ongoing development and distribution of the BNT162b2 COVID-19 vaccine, positioning updated formulations as the cornerstone of its commercial portfolio. As SARS-CoV-2 continues to evolve, the Mainz-based biotechnology firm is prioritizing the production of vaccines specifically designed to target currently circulating variants, maintaining its role as a primary … Read more